• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    I

    Innsbruck Medical University

    院校EST. 2004
    1,519论文总数
    1万引用总数

    The Medical University of Innsbruck (German: Medizinische Universität Innsbruck) is a university in Innsbruck, Austria. It used to be one of the four historical faculties of the Leopold-Franzens-Universität Innsbruck and became an independent university in 2004..

    论文量&引用量时间轴

    机构学者

    论文(1524)

    年份
    起
    –
    止
    排序
    1Clinical Insight in Schizophrenia: Time-specific Associations with Symptoms, Cognition and Antipsychotic Mechanisms
    Lena Antonsen Stabell,Erik Johnsen, Rune Andreas Kroken,Else-Marie Løberg,Inge Joa,Solveig Klæbo Reitan, Maria Rettenbacker,Rolf Gjestad

    Background Impaired clinical insight in schizophrenia is associated with poor treatment adherence and outcomes. Previous research on the influence of symptoms, cognition, and antipsychotic exposure has been inconclusive and restricted to multi-episode samples. We examined time-specific associations between overall psychopathology, cognitive functioning, antipsychotic D₂ receptor mechanisms, antipsychotic exposure and dosage, and insight, whether these associations changed over time, and whether dosage moderated them. Methods In 144 individuals with schizophrenia, including antipsychotic-naïve and previously treated participants, multiple regressions were conducted at five cross-sectional time points and examined changes in associations over one year. Insight was assessed using PANSS item G12. Symptom severity was represented by the sum of the remaining PANSS items (mPANSS). Antipsychotic exposure was quantified as cumulative Defined Daily Doses and classified as dopamine antagonists (DA) or partial agonists (DPA). Cognitive functioning was expressed as a mean t-score. Results Greater symptom severity was consistently associated with poorer insight across time points and was the only variable showing a linear increase in strength over time. Higher DPA doses were associated with poorer insight at baseline and 12 months, but improved insight at 12 weeks. Higher cognitive functioning was associated with better insight at baseline and interacted with lower doses at 6 weeks and 12 months. No consistent associations were observed in antipsychotic-naïve participants. Conclusion Clinical insight was most consistently associated with symptom severity, with an increasingly robust association over time, highlighting the need to assess insight across the symptom spectrum, including when symptoms are mild and independently of antipsychotic dosage.

    2027Schizophrenia Research Cognition(2027)
    引用
    AI阅读
    加入学术空间
    2Tumor-associated Neutrophil Heterogeneity in Prostate Cancer: Functional Plasticity, Phenotypic States, and Therapeutic Implications
    Felix Melchior,Stefan Salcher,Andreas Pircher,Isabel Heidegger

    Background Prostate cancer (PCa), the most frequently diagnosed malignancy in men, shows only limited responses to conventional immunotherapeutic strategies, largely attributed to its immunologically “cold” tumor microenvironment (TME), which is characterized by myeloid cell populations and comparatively sparse infiltration of effector T lymphocytes. Neutrophils, the most abundant myeloid cells, are increasingly recognized as active regulators of tumor progression, yet their heterogeneity in PCa remains poorly characterized. Aims This narrative state-of-the-art review addresses several questions: How do cellular and molecular cues in the TME shape tumor-associated neutrophils (TANs) in PCa and which mechanisms govern their plasticity? Do they have prognostic or even therapeutic significance and what are methodological obstacles in TAN research? Methods A non-systematic peer-reviewed literature search across PubMed, Embase, and the Cochrane Library was performed from 2000 to March 2026. Findings Distinct TAN states are linked to CXCL1/IL-8-CXCR2-driven chemotaxis, IL-6 and IL-23-STAT3-mediated immunosuppression, and effector functions such as neutrophil extracellular trap formation. Spatial and single-cell analyses indicate that these functional states are shaped by local tumor-derived signals and therapeutic pressure, with potential impact on androgen receptor signaling and treatment resistance. However, neutrophil-specific biomarkers and clinically actionable targets remain limited, partly because neutrophils are technically challenging to capture in standard single-cell workflows. Collectively, state-of-the-art evidence positions TAN heterogeneity as an underexploited prognostic and therapeutic axis in PCa, one that merits further mechanistic characterization to translate TAN-based biomarkers and immunomodulatory strategies into clinical practice.

    2027Translational Oncology(2027)
    引用
    AI阅读
    加入学术空间
    3Interest in Clinical Trial Participation in Parkinson's Disease: Insights from a Nationwide Registry
    Marina Peball,Beatrice Heim, Monika Buchart,Victoria Sidoroff,Florian Krismer, Fabienne Lehner,Atbin Djamshidian,Philipp Mahlknecht,Christoph Müller,Alessandra Fanciulli,Petra Schwingenschuh,Karoline Wenzel,

    Objective To compare (socio-)demographic, clinical, and functional characteristics of Parkinson's disease (PD) patients interested in clinical trial participation with those who are not. Background Representative recruitment is essential for clinical trials. Identifying factors associated with interest in participation may help tailor trial designs and recruitment strategies. Methods We analyzed cross-sectional data from a nationwide PD registry in Austria. Participants were dichotomized according to interest in clinical trial participation at inclusion, and group differences were statistically determined. Predictors of interest were selected using logistic regression with LASSO regularization. Results Among 543 PD patients, 395 (72.7%) expressed interest in clinical trial participation. Interested patients were younger (67.65 ± 10.16 vs. 72.76 ± 9.08 years, p < 0.001), had a shorter disease duration (9.24 ± 6.81 vs. 11.68 ± 8.64 years, p = 0.003), and less advanced disease, reflected by lower Hoehn and Yahr-stages (median 2.00 ± 1.00 vs. 3.00 ± 1.00, p < 0.001) and MDS-UPDRS-scores (all p < 0.001). Interested patients were also less likely to be functionally dependent (36.2% vs. 58.5%, p < 0.001), receive care allowance (24.8% vs. 41.9%, p < 0.001), or live in care facilities (2.8% vs. 10.1%, p = 0.001). Sex and motor fluctuations did not differ (all p > 0.085). LASSO regression identified absence of postural instability and dementia, younger age, and not being widowed as the strongest predictors of positive interest to participate in clinical trials. Conclusions Interest in clinical trial participation among PD patients is related to younger age, lower disease burden, and greater functional independence. Patients with more advanced disease and disability appear less interested, highlighting potential challenges for designing and interpreting clinical trials.

    2027Parkinsonism & Related Disorders(2027)
    引用
    AI阅读
    加入学术空间
    4Opinion: Ligand Identity Ambiguity in LNP-induced Metastasis Promotion Via TLR9-MyD88/cGAS-STING-dependent NETosis – Endogenous Mtdna or Exogenous Bacterial PAMPs?
    Hartmut H. Glossmann

    Wang and colleagues recently reported that lipid nanoparticle (LNP) administration promotes experimental pulmonary tumor metastasis through TLR9-MyD88- and cGASSTING-mediated neutrophil extracellular trap (NET) formation, invoking mitochondrial DNA (mtDNA) released from necrotic muscle cells as the activating ligand. This Opinion challenges a fundamental assumption underlying that interpretation: because TLR9 recognizes unmethylated CpG dinucleotides shared equally by mtDNA and bacterial DNA, and cGAS detects double-stranded DNA in a sequence-independent manner, the genetic rescue experiments are equally consistent with bacterial nucleic acid or lipopolysaccharide (LPS) contamination of the LNP preparations. Standard endotoxin detection methods, including the Limulus amebocyte lysate assay, are demonstrably unreliable in lipid matrices, where LPS lipid A inserts stably into hydrophobic domains and evades detection. Total lipid A quantification by EndoQuant (acid hydrolysis/HPLC-MS/MS), 16S rDNA analysis, polymyxin B pretreatment, and amplicon sequencing are required to resolve ligand identity. Until these controls are applied, the mtDNA hypothesis and a manufacturing contamination hypothesis remain equally supported by the available data — a distinction with profoundly different regulatory and clinical implications for LNP-based therapeutics.

    2027NANO TODAY(2027)
    引用
    AI阅读
    加入学术空间
    5In Vitro and in Vivo Study of Green-Synthesized Zinc Oxide Nanoparticles As a Novel Anticoccidial Agent.
    Shaimaa M. Kasem, Nabila M. Mira,Mohamed A. Dkhil, Heba Ismaeil,Saeed El-Ashram,Andreas Meryk, Hend M. Alharbi,Rewaida Abdel-Gaber

    Coccidiosis, a parasitic disease in animals, is often treated with coccidiostats, but their excessive use has led to drug resistance, reducing treatment efficacy. This study sought to investigate the in vitro and in vivo anticoccidial capacity of zinc oxide nanoparticles using Coriandrum sativum extract (CSE-ZnONPs) against Eimeria papillata. CSE-ZnONPs were synthesized and characterized via transmission electron microscopy (TEM) and energy dispersive X-ray spectroscopy (EDX). E. papillata oocysts were treated in vitro with decreasing selected concentrations from CSE-ZnONPs (100 − 0.5 mg/ml K2Cr2O7) of CSE-ZnONPs for 96 h as part of a sporulation inhibition assay. For In vivo, five groups (G) of mice were utilized: G1: control group (Non-Infected), G2: received CSE-ZnONPs, G3: infection group with 10³ sporulated oocysts (Infected). G4: infected and treated with CSE-ZnONPs at a dosage of 50 mg/kg b.w. (Infected + CSE-ZnONPs). G5: infected and treated with amprolium at a dosage of 120 mg/kg b.w. (Infected + Amp). The treatments were persisted for five days. In vitro results indicated that CSE-ZnONPs markedly decreased sporulation rates and caused morphological damage in E. papillata oocysts. The in vivo oral administration of CSE-ZnONPs to infected mice considerably reduced the numbers of jejunal endogenous stages and notably decreased their morphometric dimensions. Immunohistochemistry demonstrated a downregulation of Cluster of Differentiation 4 (CD4) and Inducible Nitric Oxide Synthase (iNOS) expression, whereas biochemical antioxidant studies indicated reduced nitric oxide and malondialdehyde levels, alongside elevated superoxide dismutase and catalase activity. ELISA verified reduced serum concentrations of interferon-γ, tumor necrosis factor-α, interleukin-10, and iNOS in the treated mice. CSE-ZnONPs possess a promising potent in vitro sporulation inhibition and in vivo anticoccidial, antioxidant, anti-inflammatory and immuno-therapeutic properties against E. papillata.

    2026Acta Parasitologica(2026)引用:52
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1524 篇论文

    合作机构(100)

    维也纳医科大学合作论文 170
    格拉茨医科大学合作论文 129
    因斯布鲁克大学合作论文 71
    因斯布鲁克医科大学合作论文 47
    约翰·开普勒林茨大学合作论文 42
    伯尔尼大学合作论文 37
    慕尼黑工业大学合作论文 37
    帕拉塞尔苏斯医学院合作论文 37
    慕尼黑大学合作论文 35
    牛津大学合作论文 33

    机构统计